Shamburg News · 8-K filed Nov 12, 2026, 7:10 AM EST

Pelthos Therapeutics Reports Third Quarter 2026 Results; Zelsuvmi Net Revenue Up 114%

PTHS · Pelthos Therapeutics Inc.

  • Earnings
  • Material agreement
  • Financing
  • Materiality: high

On November 12, 2026, Pelthos Therapeutics Inc. reported financial results for the three and nine months ended September 30, 2026, in a press release furnished as Exhibit 99.1. Third-quarter net product revenue for Zelsuvmi was $15.2 million, up 114% from $7.1 million a year earlier, and the net loss was $(7.9) million, compared with $(16.2) million in the prior-year quarter. The company also disclosed a pending merger with Castle Creek Biosciences, expected to close by the end of the first quarter of 2027, and a $10.0 million additional draw under its Horizon Technology Finance loan.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001919246-26-000134.

Written from the filing by Shamburg Markets. Figures are as reported by the company.